Faculty Advisor

Dempski, Robert E.

Center

University of Massachusetts Medical Center

Abstract

Hepatitis C virus (HCV) infection can cause serious liver disease. Efforts to eliminate the virus involve the development of novel drugs designed to disrupt viral replication. One of the ways to inhibit the virus is by targeting the HCV enzyme NS3/4A protease. MK-5172 is a potent protease inhibitor recently approved by the FDA for the treatment of HCV. As part of this project, I synthesized four new analogues of MK-5172. These analogues, which lack the methoxy group on the quinoxaline, are either linear or have different macrocyclization than MK-5172. The compounds were tested for enzyme inhibitory activity using kinetic assays. The new macrocyclic analogues show potent inhibitory activity against wild-type NS3/4A protease and the D168A drug resistant variant.

Publisher

Worcester Polytechnic Institute

Date Accepted

April 2016

Major

Biochemistry

Project Type

Major Qualifying Project

Accessibility

Restricted-WPI community only

Advisor Department

Chemistry and Biochemistry

Project Center

University of Massachusetts Medical Center

Available for download on Sunday, April 28, 2019

Your accessibility may vary due to other restrictions.

Share

COinS